Novartis’ Judith Love says UAE is a strategic hub for pharma innovation
Across the GCC, Novartis continues to expand in oncology, cardiovascular, renal and metabolic diseases, immunology, and neuroscience, while also investing in advanced therapy platforms
07 February, 2026
TT
16
The UAE is positioning itself as a global reference point for pharmaceutical innovation, driven by regulatory maturity, public-private collaboration, and a clear commitment to advancing healthcare, according to Novartis, one of the world’s largest pharmaceutical companies.
The UAE pharmaceutical market is valued at $4.15bn and is projected to double by 2033, according to the Emirates Drug Establishment. Industry leaders say the country’s strength lies not just in market size but in its ability to provide a predictable, investment-friendly environment for global life sciences companies.
Mohamed Ezz Eldin, Novartis GCC Cluster head, said regulatory evolution has had a direct impact on patient access. “We see ourselves as a long-term partner to the UAE government and healthcare system. Our priority is to accelerate access to innovative medicines through close collaboration with regulators, payers, providers, and other stakeholders,” he said. Fast-track reviews, early access pathways, and transparent pricing mechanisms have enabled the UAE to become a reference for efficient access to innovation.
Across the GCC, Novartis continues to expand in oncology, cardiovascular, renal and metabolic diseases, immunology, and neuroscience, while also investing in advanced therapy platforms, including cell and gene therapies and radioligand therapies. “Our approach is innovation-driven, but always patient-centric,” Ezz Eldin added.
Novartis’ role in the UAE extends beyond launching medicines, says Eldin
Novartis’ role in the UAE extends beyond launching medicines. Through early access pathways, patients with spinal muscular atrophy were among the first globally to receive advanced therapies. “The UAE has shown that when trust exists between regulators and industry, innovation can reach patients faster than in many developed markets,” Ezz Eldin noted.
Judith Love, regional president Asia Pacific, Middle East and Africa at Novartis, highlighted the strategic importance of the UAE and GCC. “There is a strong appreciation for cutting-edge healthcare across the region. When governments, regulators, and industry share the same vision, collaboration becomes seamless,” he said. National strategies such as UAE Vision 2031 and Saudi Vision 2030 align with Novartis’ priorities in innovation, access, and sustainability, giving the company confidence to invest.
The region’s population growth and high burden of non-communicable diseases, such as cardiovascular disease and diabetes, further underscore its strategic significance for Novartis.
A defining feature of the UAE healthcare ecosystem, according to Novartis, is “day zero access.” In the past year, five Novartis medicines were approved in the UAE within days of FDA approval, and four patients with spinal muscular atrophy were treated before any other country globally.
Public-private partnerships are the way forward for pharma innovation
Public-private partnerships underpin this progress. Novartis participates in the Genomic Innovation Consortium, leveraging the Emirati Genome Program and linking genomic, electronic medical records, and biobank data to support precision medicine.
The company also collaborates with the Emirates Oncology Society and the Pink Caravan to improve awareness, screening, and early intervention.
Looking ahead, Novartis plans to expand innovation across cardiovascular disease, neuroscience, immunology, oncology, and areas with unmet medical needs. The UAE’s pharmaceutical sector, industry leaders say, is emerging as a blueprint for how ambition, regulation, and partnership can work together to shape the future of healthcare.
Read: Novartis Gulf’s Mohamed Ezz Eldin on the region’s key healthcare trends


















